Eli Lilly Rises 2.7% as Zepbound Shows Promise in Treating Sleep Apnea

Gelonghui April 17 | Eli Lilly (LLY.US) rose 2.7% to $767. On the news front, Eli Lilly stated that its popular weight-loss drug Zepbound showed potential in treating sleep apnea patients in two late-stage clinical trials. The company plans to present the trial results at an upcoming medical conference and submit them to the U.S. Food and Drug Administration (FDA) and regulatory agencies in other countries by mid-year.